CLGN
CollPlant Biotechnologies Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$3.56
−1.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 318.0K | 2.4M | 515.0K | 11.0M | 299.0K |
| Cost of Revenue | 2.0M | 1.7M | 2.7M | 3.1M | 1.5M |
| Gross Profit | (1.7M) | 624.0K | (2.1M) | 7.9M | (1.2M) |
| Operating Expenses | |||||
| R&D Expense | 6.9M | 8.2M | 10.5M | 10.5M | 10.3M |
| SG&A Expense | 3.8M | 3.9M | 4.6M | 4.9M | 5.7M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 10.7M | 12.1M | 15.1M | 15.4M | 15.9M |
| Cost and Expenses | 12.7M | 13.9M | 17.8M | 18.5M | 17.4M |
| Operating Income (EBIT) | (12.4M) | (11.5M) | (17.3M) | (7.5M) | (17.1M) |
| Non-Operating | |||||
| Interest Income | 42.0K | 380.0K | 738.0K | 788.0K | 321.0K |
| Interest Expense | 150.0K | 15.0K | 17.0K | 10.0K | 34.0K |
| Net Interest Income | (108.0K) | 365.0K | 721.0K | 778.0K | 287.0K |
| Other Non-Op Income/Expense | (108.0K) | (6.0K) | 642.0K | 493.0K | 172.0K |
| Non-Operating Income (excl Interest) | (42.0K) | (9.0K) | (659.0K) | (503.0K) | (206.0K) |
| EBT (Pre-Tax Income) | (12.5M) | (11.5M) | (16.6M) | (7.0M) | (16.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (12.5M) | (11.5M) | (16.6M) | (7.0M) | (16.9M) |
| Earnings from Cont. Ops | (12.5M) | (11.5M) | (16.6M) | (7.0M) | (16.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (12.5M) | (11.5M) | (16.6M) | (7.0M) | (16.9M) |
| Per Share | |||||
| Basic EPS | ($9.39) | ($9.40) | ($14.50) | ($6.20) | ($15.20) |
| Diluted EPS | ($9.39) | ($9.40) | ($14.50) | ($6.20) | ($15.20) |
| Revenue Per Share | $0.22 | $1.94 | $0.45 | $9.62 | $0.27 |
| Shares | |||||
| Basic Shares Outstanding | 1.4M | 1.2M | 1.1M | 1.1M | 1.1M |
| Diluted Shares Outstanding | 1.4M | 1.2M | 1.1M | 1.1M | 1.1M |
| Profitability Metrics | |||||
| EBITDA | (11.5M) | (10.6M) | (15.6M) | (5.9M) | (15.8M) |
| D&A | 846.0K | 912.0K | 1.0M | 1.1M | 1.1M |
| EBIT | (12.4M) | (11.5M) | (16.6M) | (7.0M) | (16.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026